Whitepaper: Drug repurposing trends and strategic approaches for shortening timelines
Posted: 2 July 2021 | Thermo Fisher Scientific | No comments yet
As the complexity of drug development increases, so does the industry’s focus on strategies and solutions that can help bring advanced products to market as quickly as possible.
Lowering the cost of R&D is also a key factor, as new chemical entities and de novo drugs in clinical phases face high attrition rates, with companies losing significant investments in non-viable candidates. One approach to avoiding this fate is drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.
Related content from this organisation
- ebook: Twin-screw extrusion for pharmaceutical applications
- Biopharmaceuticals contributing to manufacturing outsourcing trend
- Biologics driving continuous bioprocessing market expansion
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Drug development trends: insight from Thermo Fisher’s Anil Kane
Issue
Related topics
Drug Development, Research & Development (R&D), Therapeutics
